1. Academic Validation
  2. Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors

Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors

  • ACS Med Chem Lett. 2025 Apr 14;16(5):790-796. doi: 10.1021/acsmedchemlett.4c00637.
Liuyan Hu 1 2 Zhi Zhao 2 Shujing Zhang 3 Lei Yang 4 5 Wenjie Cui 6 Tianwen Hu 6 Jin Suo 4 Haiguo Sun 4 5 Qiumeng Zhang 4 Leike Zhang 7 Weiliang Zhu 4 5 Zhijian Xu 4 5 Yumin Zhang 7 Xiangrui Jiang 8 4 5 Yan Zhang 4 5 8 Jingshan Shen 4 5
Affiliations

Affiliations

  • 1 School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
  • 2 Yangtze Delta Drug Advanced Research Institute and Yangtze Delta Pharmaceutical College, Nantong 226133, China.
  • 3 Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
  • 4 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 5 University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
  • 6 Vigonvita Shanghai Co., Ltd, Shanghai 201210, China.
  • 7 State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430071, China.
  • 8 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Abstract

The 3CL protease (3CLpro) of SARS-CoV-2 is a key enzyme that plays an essential role in mediating viral replication and transcription. In this study, we synthesized and evaluated a series of peptidomimetic compounds containing a tetrahydropyrrole spirodihydroindolone moiety. Among the target compounds, 13c and 17d exhibited obvious 3CLpro inhibitory activities with IC50 = 3.71 and 6.21 nM, respectively. In metabolic stability testing of liver microsomes, compound 13c showed improved stability in human liver microsomes. In addition, 13c displayed significant anti-SARS-CoV-2 activity and high safety in Vero E6 cells (EC50 = 19.26 nM, SI > 400). Further investigations indicated that 13c showed potent activity against HCoV-OC43 and favorable safety in Huh7 cells (EC50 = 61 nM, SI > 100). These findings suggest that compound 13c is a promising lead compound in the development of novel 3CLpro inhibitors.

Figures
Products